6 results about "Medication abuse" patented technology

The present application relates to the field of immunochromatography, in particular to a sample pad treatment method, a detection method and a chromatography test paper for drug abuse detection, and discloses an immunochromatography test paper for drug abuse detection, which is characterized by a sample pad treatment liquid containing Pluronic F-127.

Compositions and methods are provided to determine occupancy level of opioid receptors in a subject. The disclosed methods may be performed non-invasively in the inner ear of the subject, and may be performed at a point-of-care location to provide guidance to a practitioner on tapering on pharmacotherapy or on a patient's risk of relapse for substance abuse.

An orally disintegrating pharmaceutical tablet comprising: between 0.1 and 21 wt % of cariprazine or its pharmaceutically acceptable salts, between 0.1 and 15 wt % of a disintegrant, between 0.1 and 5 wt % of colloidal silicon dioxide, between 0.1 and 10 wt % of a taste masking agent, between 0.1 and 5 wt % of a lubricant, and up to 100 wt % of a diluent, the percentage being expressed with regard to the total weight of the pharmaceutical tablet. Said composition for use in the treatment and / or prevention of pathological conditions which require the modulation of dopamine receptors, selected from the group of psychoses, drug abuse, cognitive impairment accompanying schizophrenia, mild-to-moderate cognitive deficits, dementia, psychotic states associated with dementia, eating disorders, attention deficit disorders, hyperactivity disorders in children, psychotic depression, bipolar disorder, paranoid and delusional disorders, dyskinetic disorders, anxiety, sexual dysfunction, sleep disorders, emesis, aggression and autism.

1. The name of the design product: drug screening reagent card. 2. The use of the design product: used for qualitative detection of specific drug components in human urine samples to screen for drug abuse. 3. The design points of the design product: the combination of shape, pattern and color. 4. The picture or photo that best indicates the design points: combination state diagram. 5. The design for which protection is sought contains color.

Provided herein are pharmaceutical compositions comprising a denatonium salt and a pharmaceutical agent. Also provided herein are methods for reducing a risk of drug abuse comprising use of a denatonium salt to decrease the likelihood of improper ingestion of a pharmaceutical agent. Also provided herein are methods for making the test of a drug less palatable comprising a subclinical dose of a denatonium salt.

This invention relates to the pharmaceutical field, and particularly to the use of substances that specifically bind to S-100B protein in the preparation of diagnostic or prognostic products for acute retinal necrosis (ARN). By detecting the level of S-100B protein in the aqueous humor, the extent of optic nerve damage caused by ARN can be objectively and accurately observed. This can aid in the early clinical diagnosis of ARN, enabling timely and appropriate treatment, effectively reducing the risk of retinal detachment and blindness, and helping clinicians predict disease progression and visual prognosis, achieving early intervention, precision treatment, and reducing drug abuse and waste of medical resources.